Join us on our journey to deliver groundbreaking, all-natural cancer treatments backed by science
For over 20 years, NF Skin has been a leader in wellness innovation. Founded in 2017, the Physicians Grade brand made history as the first CBD brand sold in national retail chains, achieving a $45M EPDA value by 2019. In late 2024 Repyr Group LLC was formed. We acquired Physicians Grade and its IP on several cutting-edge products. Today, we’re pushing boundaries with REPYR-SC1, a hemp-derived extract poised to transform cancer care.
Revolutionizing Cancer Care with Nature’s Power
“REPYR-SC1 killed 100% of skin cancer cells in 36 hours.” – University of Miami
2017: The Birth of Physicians Grade
Our story begins in 2017 when NF Skin LLC founded Physicians Grade, a wholly owned brand that would soon make waves in the wellness industry. From the start, NF Skin set out to blend emerging ingredients with rigorous research, positioning themselves at the forefront of the private label market. Little did they know this was the first step toward something much bigger.
2018: Partnering with Pioneers
In 2018 NF Skin began their relationship with the University of Miami Miller School of Medicine’s Clinical Trial Department. Their initial collaboration on both hair loss and acne products marked the beginning of a deep dive into hemp-based innovations. With the commercialization of hemp gaining momentum, there was an opportunity to explore its potential beyond traditional wellness—and into the realm of life-saving medicine.
2019: Breaking Ground in Retail
By 2019 Physicians Grade had achieved a historic milestone: we became the first CBD brand to be sold in national retail chain stores. With an estimated EPDA (Earnings Per Distribution Agreement) value of $45 million, they proved that their vision resonated with consumers and industry leaders alike. Yet even as they celebrated their success, sights were set on a loftier goal—combating cancer.
2020-2023: Seven Years of Research Begin
Thus began testing the oil to address cancers such as squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma, leukemia, lung, and prostate cancer. The catalyst for further research became clear with the success of the oil in helping various illnesses. Friends and family with various ailments who were given the oil all found it "Miraculous". Their feedback and testimonials precipitated further research leading to a cal with Dr. Jimenez at University of Miami.
July 2024: A Breakthrough Moment
In July 2024 everything changed. Preclinical trials at the University of Miami confirmed what the team had long believed: Hutson Oil (REPYR-SC1) was something truly extraordinary. Lab results showed a 100% kill rate of skin cancer cells within just 36 hours using only 5 microliters—roughly the size of a pinhead. Even a single 1-microliter dose eliminated 95% of cells within 48 hours.
The breakthrough didn’t stop there. Hutson Oil also demonstrated strong activity against metastatic melanoma, leukemia, lung cancer and prostate cancer cells, opening the door to even greater possibilities.
Summer 2024: Building Strategic Momentum
As excitement around the research grew, NF Skin explored strategic paths to accelerate development. Early summer 2024 brought a series of investor meetings to evaluate opportunities for partnership and growth. It quickly became clear: while interest in the overall company was strong, the real spotlight was on the potential of Physicians Grade and the groundbreaking REPYR-SC1 technology.
By August 2024, a dynamic group of investors committed to acquiring the Physicians Grade brand and the REPYR intellectual property, making an initial investment to set the stage for future expansion.
September 2024: Expanding the Brand
Concurrently, Physicians Grade introduced a new range of wellness products—including premium CBD supplements, topicals and pain relief creams. These launches not only strengthened brand awareness but also helped position Physicians Grade as a leader in health and wellness innovation.
December 2024–January 2025: A New Era Begins
On December 11, 2024 a formal teaming agreement was signed, paving the way for a powerful new chapter. In January 2025, the first major investment milestone was achieved and two new entities were officially launched:
Repyr Group LLC — dedicated to advancing the research, development, and licensing of REPYR-SC1.
Physicians Grade LLC — focused on bringing best-in-class health and wellness products to a growing market.
Today, all research, manufacturing and operational activities for REPYR-SC1 are led by Repyr Group LLC, as Physicians Grade continues to expand its mission of delivering wellness solutions for a healthier tomorrow.
February 2025: Sharing Our Findings with the World
This past February we reached a proud milestone: the Eastern-Atlantic Student Research Forum (ESRF) at the University of Miami published two abstracts showcasing REPYR-SC1’s cancer-inhibitory activity. The spotlight was on its effects against SCC, BCC, prostate cancer and T-lymphocytes, with evidence of immunomodulatory and antineoplastic power. The scientific community took notice—and so did we. This was our cue to accelerate.
February 2025: Product Rollout Begins
That same month, we launched our cancer treatment and prevention products online. From skin cancer transdermal patches and topical balms to 4000mg phytocannabinoid tinctures and gummies, these offerings brought our research to life. Backed by University of Miami clinical documentation, they represent the culmination of years of dedication—and the start of a new chapter.
April 2025: Where We Are Today
As of today we’re at a “proof of concept” stage with REPYR-SC1. Our preclinical results are electrifying and we’re ready to take the next step: formal clinical trials. We’re partnering with FDA-compliant manufacturers like NutraLife Biosciences and Prime Matter Labs to ensure quality and scalability. Breast cancer testing is underway and our expert University of Miami partners—led by Dr. Joaquin Jimenez, Sylvia Daunert and Sapna Deo—continue to push the boundaries of what’s possible.
The Future: More Research, More Development
As we continue to present our findings to the public and to the medical community, we invite you to reach out with any questions or to sign up for our "Updates" mailing list.
Our journey is far from over, but every step brings us closer to a cure. Stay tuned, because at REPYR, the best is yet to come.
At REPYR, we’re driven by a singular mission: to harness nature’s power and cutting-edge science to revolutionize cancer care. Our story is one of persistence, breakthroughs, and a relentless pursuit of solutions that can change lives. Here’s a look at the key milestones in our journey so far—and a glimpse of what’s ahead.
Our Journey to a Cancer Cure:
A Timeline of Innovation at REPYR
- "100% kill rate of squamous, basal cell carcinoma, and melanoma cells in preclinical trials."
- "Effective against leukemic, lung, and prostate cancer cells with minimal doses."
- "Presented at the Eastern-Atlantic Student Research Forum (ESRF), February 2025."
- "Presented at the American Association for Cancer Research (AACR), April 2025"
Real Science / Real Results
Seen above, 100% of melanoma cells were killed at the 36-hr mark using the 10 μL dose, where as 5 μL managed to exterminate 97% of melanoma cells by 48-hr mark. We conclude REPYR-SC1 is effective against various cancers of the skin.
